Article
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2007
Jamieson David, Wilson Kerrie, Pridgeon Simon, Margetts Jane P, Edmondson Richard J, Leung Hing Y, Knox Richard, Boddy Alan V
Abstract excerpt
PURPOSE: NRH:quinone oxidoreductase 2 (NQO2) is a homologue of NAD(P)H:quinone oxidoreductase 1 (NQO1). Despite 54% homology with human NQO1, NQO2 has little endogenous enzymatic activity. However, NQO2 has potential as a therapeutic target because the addition of the nonbiogenic electron donor dihydronicotinamide riboside (NRH) selectively potentiates the bioactivation of the alkylating agent tretazicar (CB...
Topics
- Female
- Humans
- NAD(P)H Dehydrogenase (Quinone)
- Niacinamide
- Ovarian Neoplasms
- Polymorphism, Restriction Fragment Length
- Polymorphism, Single Nucleotide
- Pyridinium Compounds